BioCentury | Nov 18, 2020
Product Development

Nov. 17 Quick Takes: Phase III miss for BrainStorm’s ALS program; plus Novo, BioMarin-Deep Genomics, Lexicon, Seed-Lilly and RhoVac

...known adverse events for the class.BioMarin, Deep Genomics enter oligonucleotide dealBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) will use Deep Genomics Inc.’s...
...rare disease indiccations; financial terms are undisclosed. BioMarin will receive an exclusive option to obtain Deep Genomics’...
BioCentury | Nov 7, 2020
Management Tracks

Shah retiring from Lilly; plus moves at Trillium, Codagenix, VectivBio, Deep Genomics, Novo Ventures and Theratechnologies

...Ltd. (SIX:LONN); and Venugopal was an executive director at Intercept Pharmaceuticals Inc. (NASDAQ:ICPT).AI therapeutics company Deep Genomics Inc....
...HIV, non-alcoholic steatohepatitis and cancer therapies, hires a successor. Danielle Golovin Eli Lilly and Co. Trillium Therapeutics Inc. Codagenix Inc. Deep Genomics Inc. Novo...
BioCentury | Oct 1, 2020
Management Tracks

CVS’s Asgarian joins Thrive as CMO; plus Black Diamond names Ingram chairman and updates from MorphoSys, G1 and more

...NASDAQ:IFRX), succeeds Thomas Ulmer, who is stepping down to pursue other opportunities. Ferdinand Massari has joined AI company Deep Genomics Inc....
...CEO of Meditope Biosciences Inc. BC Staff Thrive Earlier Detection Corp. Black Diamond Therapeutics Inc. MorphoSys AG Partner Therapeutics Inc. Brii Biosciences Deep Genomics Inc. Immatics...
BioCentury | Jan 7, 2020
Financial News

Jan. 7 Financial Quick Takes: Deep Genomics raises $40M; plus Arcutis, Kintor file for IPOs, TwinStrand and RootPath

...Ventures leads Deep Genomics’ $40M series B Looking to submit INDs for two programs this year, Deep Genomics Inc....
...T cell therapy company’s seed round in 2018 (see “Sequoia China Leads Seed Round” ). BioCentury Staff Deep Genomics Inc. RootPath...
BioCentury | Oct 25, 2019
Emerging Company Profile

Deep Genomics: Letting AI take the wheel

...Deep Genomics’ platform encompasses the entire discovery and development process, Frey told BioCentury. According to Frey, Deep Genomics...
...manufacture than biologics, and a CRO can synthesize the compounds without Deep Genomics needing capabilities in-house. Deep Genomics...
...of the pharma process, but in every part,” said Khosla, who is a Deep Genomics adviser. Deep Genomics...
BioCentury | Apr 13, 2018
Company News

Wave, Deep Genomics partner for neuromuscular disease targets

...Neuromuscular disease company Wave Life Sciences Ltd. (NASDAQ:WVE) and Deep Genomics Inc. (Toronto, Ontario) partnered to identify and...
...neuromuscular disorders. The companies will evaluate oligonucleotides against potential therapeutic targets implicated in neuromuscular diseases. Deep Genomics'...
...candidate in 1Q19. Wave Life Sciences Ltd. (NASDAQ:WVE), Cambridge, Mass. Deep Genomics Inc., Toronto, Ontario Business: Neurology Allison Johnson Deep Genomics Inc. Wave...
BioCentury | Nov 23, 2015
Financial News

Deep Genomics completes venture financing

Deep Genomics Inc. , Toronto, Ontario Business: Genomics, Bioinformatics Date completed: 2015-11-18 Type: Venture financing Raised: C$5 million ($3.8 million) Investors: True Ventures; Bloomberg; angel investors WIR Staff...
BioCentury | Dec 12, 2013
Distillery Techniques

Technology: Computational models

This week in techniques Approach Summary Licensing status Publication and contact information Computational models Genome-based classification of lung tumors and treatments improves patient survival Genome-based classification of lung cancer could help improve patient survival. Human...
Items per page:
1 - 8 of 8
BioCentury | Nov 18, 2020
Product Development

Nov. 17 Quick Takes: Phase III miss for BrainStorm’s ALS program; plus Novo, BioMarin-Deep Genomics, Lexicon, Seed-Lilly and RhoVac

...known adverse events for the class.BioMarin, Deep Genomics enter oligonucleotide dealBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) will use Deep Genomics Inc.’s...
...rare disease indiccations; financial terms are undisclosed. BioMarin will receive an exclusive option to obtain Deep Genomics’...
BioCentury | Nov 7, 2020
Management Tracks

Shah retiring from Lilly; plus moves at Trillium, Codagenix, VectivBio, Deep Genomics, Novo Ventures and Theratechnologies

...Ltd. (SIX:LONN); and Venugopal was an executive director at Intercept Pharmaceuticals Inc. (NASDAQ:ICPT).AI therapeutics company Deep Genomics Inc....
...HIV, non-alcoholic steatohepatitis and cancer therapies, hires a successor. Danielle Golovin Eli Lilly and Co. Trillium Therapeutics Inc. Codagenix Inc. Deep Genomics Inc. Novo...
BioCentury | Oct 1, 2020
Management Tracks

CVS’s Asgarian joins Thrive as CMO; plus Black Diamond names Ingram chairman and updates from MorphoSys, G1 and more

...NASDAQ:IFRX), succeeds Thomas Ulmer, who is stepping down to pursue other opportunities. Ferdinand Massari has joined AI company Deep Genomics Inc....
...CEO of Meditope Biosciences Inc. BC Staff Thrive Earlier Detection Corp. Black Diamond Therapeutics Inc. MorphoSys AG Partner Therapeutics Inc. Brii Biosciences Deep Genomics Inc. Immatics...
BioCentury | Jan 7, 2020
Financial News

Jan. 7 Financial Quick Takes: Deep Genomics raises $40M; plus Arcutis, Kintor file for IPOs, TwinStrand and RootPath

...Ventures leads Deep Genomics’ $40M series B Looking to submit INDs for two programs this year, Deep Genomics Inc....
...T cell therapy company’s seed round in 2018 (see “Sequoia China Leads Seed Round” ). BioCentury Staff Deep Genomics Inc. RootPath...
BioCentury | Oct 25, 2019
Emerging Company Profile

Deep Genomics: Letting AI take the wheel

...Deep Genomics’ platform encompasses the entire discovery and development process, Frey told BioCentury. According to Frey, Deep Genomics...
...manufacture than biologics, and a CRO can synthesize the compounds without Deep Genomics needing capabilities in-house. Deep Genomics...
...of the pharma process, but in every part,” said Khosla, who is a Deep Genomics adviser. Deep Genomics...
BioCentury | Apr 13, 2018
Company News

Wave, Deep Genomics partner for neuromuscular disease targets

...Neuromuscular disease company Wave Life Sciences Ltd. (NASDAQ:WVE) and Deep Genomics Inc. (Toronto, Ontario) partnered to identify and...
...neuromuscular disorders. The companies will evaluate oligonucleotides against potential therapeutic targets implicated in neuromuscular diseases. Deep Genomics'...
...candidate in 1Q19. Wave Life Sciences Ltd. (NASDAQ:WVE), Cambridge, Mass. Deep Genomics Inc., Toronto, Ontario Business: Neurology Allison Johnson Deep Genomics Inc. Wave...
BioCentury | Nov 23, 2015
Financial News

Deep Genomics completes venture financing

Deep Genomics Inc. , Toronto, Ontario Business: Genomics, Bioinformatics Date completed: 2015-11-18 Type: Venture financing Raised: C$5 million ($3.8 million) Investors: True Ventures; Bloomberg; angel investors WIR Staff...
BioCentury | Dec 12, 2013
Distillery Techniques

Technology: Computational models

This week in techniques Approach Summary Licensing status Publication and contact information Computational models Genome-based classification of lung tumors and treatments improves patient survival Genome-based classification of lung cancer could help improve patient survival. Human...
Items per page:
1 - 8 of 8